Volume | 1,817,398 |
|
|||||
News | - | ||||||
Day High | 12.06 | Low High |
|||||
Day Low | 11.71 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | DVAX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
11.87 | 11.71 | 12.06 | 11.74 | 11.72 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,538 | 1,817,398 | $ 11.95 | $ 21,720,799 | - | 10.06 - 15.15 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:18 | 1 | $ 11.88 | USD |
Dynavax Technologies Corp Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.53B | 130.61M | - | 232.28M | -6.39M | -0.05 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Dynavax Technologies News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVAX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 11.11 | 12.065 | 11.03 | 11.49 | 1,729,358 | 0.63 | 5.67% |
1 Month | 12.07 | 12.17 | 11.03 | 11.67 | 2,120,956 | -0.33 | -2.73% |
3 Months | 12.92 | 13.265 | 11.03 | 12.16 | 1,984,734 | -1.18 | -9.13% |
6 Months | 14.835 | 15.15 | 11.03 | 12.93 | 1,891,452 | -3.10 | -20.86% |
1 Year | 10.10 | 15.15 | 10.06 | 13.19 | 1,759,618 | 1.64 | 16.24% |
3 Years | 10.11 | 21.39 | 7.09 | 12.97 | 2,179,150 | 1.63 | 16.12% |
5 Years | 6.80 | 21.39 | 1.80 | 9.83 | 2,628,328 | 4.94 | 72.65% |
Dynavax Technologies Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product. |